PMI Picard Medical, Inc.
Price Chart
Executive Summary
Picard Medical announced successful completion of an acute in vivo implant study for its next-generation Emperor Total Artificial Heart (TAH), demonstrating stable hemodynamic support with no device-related failures. The study advances development toward a fully implantable system but the device remains pre-FDA approval, and the company has a $16M market cap with no revenue from this product line disclosed.
Actionable Insight
This is a positive preclinical data readout for an early-stage medtech with a $16M market cap. The stock may see a short-term pop on the news, but the device is years away from commercialization and the company has no disclosed revenue from this platform. Given the poor historical calibration (avg T+20 alpha -24%), traders should consider taking profits quickly rather than holding through the next catalyst.
Key Facts
- Three acute implant procedures completed successfully with stable hemodynamic support and no device-related intraoperative failures.
- Emperor TAH incorporates independent dual motor ventricular system for side-specific control of systemic and pulmonary circulation.
- Device is under development and has not received FDA approval or clearance.
- Company market cap is $16M; no revenue or financial data from this press release.
- Historical performance on PMI filings shows average T+20 alpha of -24.09% with 14% win rate, indicating poor prior calibration.
Financial Impact
No financial figures disclosed; preclinical milestone with no revenue impact yet.
Risk Factors
- Emperor TAH is preclinical and requires FDA approval, which is uncertain and years away.
- Company has a $16M market cap with no disclosed revenue from this product; cash burn risk.
- Historical filings on PMI have shown poor stock performance post-event (avg T+20 alpha -24%).
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304974 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
3d ago
|
Press Release
| $0.2700 $0.3080 | ▲ +14.07% | ▲ +14.77% | $0.2596 (−3.85%) |
|
Jun 2, 2026
3d ago
|
8-K
| $0.2700 $0.3080 | ▼ −14.07% | ▼ −14.77% | $0.2596 (+3.85%) |
|
Jun 1, 2026
4d ago
|
EFFECT
| — | awaiting T+1 | — | — |
|
May 29, 2026
7d ago
|
8-K
| — | awaiting T+1 | — | — |
|
May 29, 2026
7d ago
|
Press Release
| $0.1480 $0.1684 | ▲ +13.78% | ▲ +13.51% | $0.2596 (+75.41%) |
|
May 21, 2026
15d ago
|
Press Release
| $0.1410 $0.1510 | ▼ −7.09% | ▼ −6.65% | $0.2596 (−84.11%) |
|
May 20, 2026
15d ago
|
S-1
| — | awaiting T+1 | — | — |
|
May 6, 2026
4w ago
|
424B4
| $0.2320 $0.2210 | ▲ +4.74% | ▲ +4.41% | $0.2596 (−11.90%) |
|
May 5, 2026
4w ago
|
8-K
| $0.2100 $0.2320 | ▼ −10.48% | ▼ −9.09% | $0.2596 (−23.62%) |
|
Apr 22, 2026
6w ago
|
8-K
| $0.9070 $0.8430 | ▼ −7.06% | ▼ −6.66% | $0.2596 (−71.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access